Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02595957 · ClinicalTrials.gov registry record

Genomic Services Research Program

A clinical trial of Breast Cancer and Colon Cancer, sponsored by National Human Genome Research Institute (NHGRI).

Recruiting
Registry status
5,000
Enrollment target
1
Study location

NCT02595957: Recruiting study of Breast Cancer and Colon Cancer, sponsored by National Human Genome Research Institute (NHGRI).

NCT02595957 is a study of Breast Cancer and Colon Cancer that is actively recruiting participants, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 5,000 participants, above the 2,799-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (79% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02595957, a study of Breast Cancer and Colon Cancer, is actively recruiting participants, sponsored by National Human Genome Research Institute (NHGRI).

RECRUITING
Registry status
5,000 participants
Enrollment target
1
Study location

Study Summary

Background: Genes are the instructions a person s body uses to function. Genome sequencing reads through all of a person s genes. Everyone has many gene variants, and most do not cause disease. Some gene variants called secondary findings may be important for a person s health even if they are not related to the reason why a person had genome sequencing done. Researchers want to learn more about what it means to have a secondary finding. Objectives: To learn about how gene variants may affect a person s health. To learn about how people understand their genetic test results. Eligibility: People with secondary findings from genetic testing done as part of a research study, clinical care, or other methods. Design: Participants may be asked to do an online survey and phone interview to ask what they think about their results, their healthcare, and if they talk with their family about the result. Eligible participants may be offered a visit to the NIH Clinical Center where they will be evaluated for health problems related to the secondary finding. DNA samples that were already collected may be studied. Participants may be asked to send in a second DNA sample (blood or saliva). These will be used to verify any findings. Participants who have a secondary finding can get genetic counseling.

Primary Outcome

We will assess the health impacts of SF receipt and healthcare processes affecting outcomes in SF recipients.

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2014-09-16
Est. Completion 2028-12-31

What NCT02595957 shows while recruiting

NCT02595957 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,799-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (79% higher).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT02595957 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02595957 about?

NCT02595957 is a clinical study titled "Genomic Services Research Program". Background: Genes are the instructions a person s body uses to function. Genome sequencing reads through all of a person s genes. Everyone has many gene variants, and most do not cause disease. Some gene variants called secondary findings may be important for a person s health even if they are not ...

What is the current status of trial NCT02595957?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2014-09-16. Estimated completion is 2028-12-31.

What conditions does trial NCT02595957 study?

This clinical trial studies the following conditions: Breast Cancer, Colon Cancer.

Who is sponsoring clinical trial NCT02595957?

This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02595957 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02595957's enrollment target sits among peer trials

5,000 28th of 1224 higher than 1,195 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00060541 · 5,000 participants

    Evaluation and Treatment of Neurosurgical Disorders

  • NCT00575081 · 5,000 participants

    Physiological Brain Atlas Development

  • NCT00736749 · 5,000 participants

    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

  • NCT00900198 · 5,000 participants

    Collection of Tissue Samples for Cancer Research

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02595957, the US trial registry maintained by the National Library of Medicine. NCT02595957 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.